Miles W. Behan1, MD; Alexandra J. Lansky2, MD; Sanjit Jolly3, MD; Andreas Baumbach4*, MD
1. Edinburgh Heart Centre, Edinburgh, United Kingdom; 2. Division of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA; 3. McMaster University and the Population Health Research Institute, Hamilton Health Sciences, Hamilton,
The Thrombus Aspiration in ST-Elevation Myocardial Infarction in Scandinavia (TASTE) trial was a multicentre, prospective, randomised, controlled, open-label trial comparing manual thrombus aspiration followed by PCI to PCI only in patients with ST-elevation myocardial infarction (STEMI)1. Patients were enrolled from the national Swedish Coronary Angiography and Angioplasty Registry (SCAAR) and endpoints evaluated through national registries. The primary endpoint was all-cause mortality at 30 days, and 7,244 patients with STEMI presenting within 24 hours of onset of symptoms were recruited. TASTE found no significant difference in 30-day mortality (2.8% in the aspiration group versus 3.0% in the no aspiration group, hazard ratio 0.94, 95% CI: 0.72-1.22). Rates of ...